Insights in Gynecologic Oncology
Open Access

Fertility preservation; Cryopreservation; Ovarian tissue freezing; Sperm banking; Reproductive medicine; Gametogenesis; Artificial ovaries; Medical treatments; Infertility; Ethical considerations

Introduction

Fertility preservation refers to the process of safeguarding an individual's ability to have biological children in the future, often in the face of medical treatments such as chemotherapy, radiation therapy, or other circumstances that might jeopardize reproductive health. For cancer patients, especially women, fertility can be at significant risk due to the harmful effects of chemotherapy and radiation. The advancement of fertility preservation methods provides these individuals with the opportunity to plan for future family-building. Over the past few decades, fertility preservation has evolved, with techniques becoming more accessible and sophisticated. This article reviews the current landscape of fertility preservation methods, their clinical applications, limitations, and future prospects in reproductive medicine [1].

Description

The most widely utilized method for fertility preservation is cryopreservation, which involves the freezing of sperm, eggs, and embryos. In males, sperm banking is a relatively simple and effective process, where sperm samples are collected and frozen for future use. In females, however, fertility preservation is more complex due to the limited number of eggs available at any given time. Oocyte cryopreservation, or egg freezing, has become an increasingly common technique, though it requires hormonal stimulation to harvest eggs before they are frozen. For patients who cannot undergo hormonal stimulation, ovarian tissue freezing offers a promising alternative. This method involves the removal and freezing of ovarian tissue, which can later be re-implanted or used in in vitro fertilization (IVF) [2,3].

Another emerging area of research in fertility preservation is the development of artificial ovaries, which aim to restore fertility in women who have lost ovarian function due to medical treatments. In vitro gametogenesis (IVG), a technique that involves generating eggs or sperm from stem cells, has also shown promise in animal models and may revolutionize fertility preservation in the future. These innovative technologies hold the potential to not only preserve fertility but also restore it in individuals who previously had no options [4].

Results

Studies have demonstrated the success of cryopreservation techniques, particularly sperm banking, which has been widely utilized for over 30 years. The success rates of sperm cryopreservation are high, with survival rates post-thawing typically exceeding 70%. For women, the success of egg freezing has steadily improved, with advances in culture media, cryoprotectants, and freezing protocols. The live birth rates following egg freezing are still relatively low, but they continue to improve as techniques evolve. Ovarian tissue freezing is considered more experimental, but there have been successful pregnancies reported following the transplantation of frozen ovarian tissue. The procedure is still limited by the ability to safely re-implant the tissue without the risk of reintroducing cancerous cells, as well as the potential loss of ovarian function over time. Advances in tissue engineering and the development of artificial ovaries offer promise for overcoming these limitations. In vitro gametogenesis has yet to be successfully applied to humans, but recent breakthroughs in animal models suggest it could be a game-changer in the future [5,6].

Discussion

The primary challenge in fertility preservation is ensuring that the methods are accessible to all individuals at risk of infertility, not just those with certain medical conditions or financial resources. While sperm banking is a straightforward process, egg freezing, and ovarian tissue preservation require significant financial investment and medical intervention. Furthermore, there are ethical and social considerations surrounding fertility preservation, particularly regarding the age at which individuals should begin to consider these options. The increasing use of fertility preservation among women who wish to delay childbearing for personal or professional reasons has raised questions about the societal implications of such trends [7,8]. Another key issue is the potential for exploitation, as fertility preservation is not universally accessible, and the cost can be prohibitive for many patients. Insurance coverage for fertility preservation is also inconsistent, particularly for individuals who are not undergoing medical treatments like chemotherapy. Moreover, the long-term success rates of certain techniques, such as ovarian tissue freezing and in vitro gametogenesis, are still not fully established, and further research is required to optimize these methods. Ethical concerns related to the storage and use of frozen gametes and embryos also need careful consideration. Issues such as consent, the disposition of unused embryos, and the moral implications of genetic manipulation in reproductive technologies must be addressed as the field evolves [9,10].

Conclusion

Fertility preservation is a rapidly advancing field with numerous options available to individuals facing infertility due to medical treatments or life choices. While techniques like sperm banking and egg freezing are well-established, new innovations, including ovarian tissue freezing, artificial ovaries, and in vitro gametogenesis, hold the potential to revolutionize reproductive medicine. However, challenges related to accessibility, cost, and ethical concerns remain. As research continues, the goal is to refine these techniques, improve success rates, and ensure that fertility preservation is accessible to all who need it. Future developments in this field will likely provide more personalized and effective options for individuals looking to preserve their fertility, ultimately giving them greater control over their reproductive future.

1. Franceschi S, La Vecchia C, Negri E, Guarneri S, Montella M, et al. (1994)Fertility drugs and risk of epithelial ovarian cancer in Italy.Hum Reprod9: 1673-1675.

Indexed at, Google Scholar, Crossref

2. Cusidó M, Fábregas R, Pere BS, Escayola C, Barri PN (2007) Ovulation induction treatment and risk of borderline ovarian tumors.Gynecol Endocrinol 23: 373-376.

Indexed at, Google Scholar, Crossref

3. Leibowitz D, Hoffman J (2000)Fertility drug therapies: past, present, and future.J Obstet Gynecol Neonatal Nurs 29: 201-210.

Indexed at, Google Scholar, Crossref

4. Holzer H, Casper R, Tulandi T (2006)A new era in ovulation induction.Fertil Steril 85: 277-284.

Indexed at, Google Scholar, Crossref

5. Gips H, Hormel P, Hinz V (1996)Ovarian stimulation in assisted reproduction.Andrologia28: 3-7.

Indexed at, Google Scholar, Crossref

6. Elias RT, Pereira N, Palermo GD (2017)The benefits of dual and double ovulatory triggers in assisted reproduction.J Assist Reprod Genet 34: 1233.

Indexed at, Google Scholar, Crossref

7. Shapiro BS, Daneshmand ST, Restrepo H, Garner FC, Aguirre M, et al. (2011)Efficacy of induced luteinizing hormone surge after “trigger” with gonadotropin-releasing hormone agonist.Fertil Steril95: 826–828.
8. Siegel RL, Miller KD, Jemal A (2016)Cancer statistics.CA Cancer J Clin 66: 7-30.

Indexed at, Google Scholar, Crossref

9. Li Y, Zhang JJ, Xu DP, Zhou T, Zhou Y, et al. (2016)Bioactivities and health benefits of wild fruits.Int J Mol Sci 17: 1258.

Indexed at, Google Scholar, Crossref

10. Zhou Y, Zheng J, Li Y, Xu DP, Li S, et al. (2016)Natural polyphenols for prevention and treatment of cancer.Nutrients 8: 515.

Indexed at, Google Scholar, Crossref